Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that chronic treatment with EE/LNG in female rats decreased brain concentrations of allopregnanolone, leading to reduced social and sexual behaviors; progesterone administration reversed these effects, except when finasteride was used to block the increase.

This study found that glibenclamide exhibited a cytostatic effect on MDA-MB-231 breast cancer cells, potentially mediated through K ATP channels, and enhanced the antiproliferative impact of doxorubicin.

Among women with polycystic ovary syndrome, this study found that oral contraceptives containing 20 μg ethinyl estradiol had similar effects on androgen levels as those containing 30 μg.

This review discusses the use of ethinylestradiol combined with antiandrogenic progestin for treating androgenisation symptoms and improving metabolic and menstrual health in women, but it does not provide new clinical data.

In this study, baricitinib treatment over an average of 18.5 months resulted in a 72% reduction in alopecia severity scores among patients aged 65 or older, with mild adverse effects and no severe complications reported.

This study found that baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata, with similar improvements observed in both clinician-reported and patient-reported measures.

This study found that in women with PCOS, suppressive therapy using spironolactone plus oral contraceptives improved hirsutism more effectively than either treatment alone, with initial scores predicting success.

This review explores plant-based pharmacological advances for treating polycystic ovary syndrome, reporting no new clinical results but highlighting potential benefits for menstrual cycle regulation and testosterone reduction.

This study highlights a paradox where valproic acid, known for causing hair loss, may also promote hair growth when applied topically.

In this study, oral dienogest combined with ethinylestradiol provided effective contraception with a Pearl Index of approximately 0.2 and improved androgenic symptoms without significant metabolic effects.

Mesotherapy with bicalutamide has limited effectiveness for female hair loss.

In this study, participants receiving a 50-mg maintenance dose of ritlecitinib reported greater improvements in emotional and activity limitations due to hair loss by Week 48 compared to those on a 10-mg dose.

This study provides a narrative review suggesting GLP-1 receptor agonists could optimize metabolic health before conception in women with PCOS, but not necessarily improve fertility outcomes, emphasizing individualized use and the need for further research to confirm their reproductive benefits and safety.

This abstract reviews the management of polycystic ovary syndrome and highlights the potential benefits of lifestyle changes over metformin in reducing type 2 diabetes risk, yet reports no new clinical outcomes.

In this retrospective study conducted at Nishtar Hospital, nab-paclitaxel combined with radiotherapy provided similar survival outcomes to cisplatin in treating early-stage cervical cancer, with lower hematologic and gastrointestinal toxicity, though alopecia was more common.

This study found that resveratrol improved menstrual regularity and reduced hair loss in women with PCOS, but did not affect androgen levels or metabolic profiles.

In this analysis of two trials, baricitinib showed eyebrow and eyelash regrowth in severe alopecia areata patients with greater than 20% scalp hair loss at Week 36, compared to placebo.

This study identified seven novel CYP17A1 inhibitor scaffolds as potential leads for treating polycystic ovary syndrome through an in silico approach, demonstrating favorable interactions, drug-like properties, and predicted bioactivities warranting further experimental validation.

This phase II study found that gemcitabine plus paclitaxel showed promising activity and manageable toxicity as first-line therapy for recurrent or metastatic breast cancer, with a 35% overall response rate.

The authors concluded that capecitabine and high-dose toremifene may be an effective treatment option for patients unable to undergo anthracycline or taxane therapies, based on one woman's cancer management.

This article suggests using oral contraceptives with antiandrogenic properties for women with virilization symptoms like acne and advises higher doses of antiandrogens for severe acne, androgenic alopecia, or idiopathic hirsutism.

This review discusses the potential of combined therapy with WP 631 and epothilone B for ovarian cancer, but reports no new clinical results.

This study found that patients, oncologists, and payers prioritize a significant improvement in efficacy to justify the added risks and costs when considering CDK4/6 inhibitors combined with endocrine therapy for early-stage breast cancer.

Dutasteride is more effective for male pattern baldness than finasteride, and black cohosh extract BNO 1055 is as effective as conjugated estrogens in treating postmenopausal symptoms, with added benefits in reducing sweating and mental symptoms.

This study focused on baricitinib's effect on patients with severe alopecia areata, highlighting its efficacy for hair regrowth and its potential to improve health-related quality of life and psychological symptoms, as seen in two phase 3 trials.

Birth control pills and anti-androgen medications help manage hair growth, acne, and hair loss in women with PCOS.

This article compares cabergoline and bromocriptine for treating hyperprolactinemic amenorrhea and reports no specific findings.

In this study, neoadjuvant treatment with durvalumab combined with albumin-bound paclitaxel and carboplatin in patients with driver gene-negative stage III NSCLC showed a 65% objective response rate and was associated with high pathological response rates and improved immune function, with most adverse events being mild.

This randomized clinical trial found that oral contraceptives containing desogestrel were associated with more adverse effects on serum lipids and blood pressure compared to those containing drospirenone in patients with polycystic ovary syndrome.

In this study, baicalin from Scutellaria baicalensis decreased androgen levels in both cells and PCOS model rats by inhibiting key gene expression, suggesting it may be a potential treatment for hyperandrogenism in PCOS.